Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Alector Inc.

ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands

ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.

Deals Neurology

GSK Dives Into Neurology With £30m Oxford University Pact

After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.

Deals Neurology

Cautious Optimism For Alzheimer's Mounts Among Industry R&D Leaders

Some big pharma R&D leaders have signaled enhanced interest in neuroscience R&D – and Alzheimer's more specifically – following FDA's approval of Biogen's Aduhelm based on biomarkers.

Neurology Research & Development

AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid

Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Alector LLC
UsernamePublicRestriction

Register